OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialRecruiting

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

A phase 1/2 trial of IN10018 and Furmonertinib in non-small-cell lung cancer, run by InxMed (Shanghai) Co., Ltd., now recruiting.